Doximity, Inc. (DOCS) vs 10x Genomics (TXG)
Doximity, Inc. and 10x Genomics are both Health Information Services companies. 10x Genomics is the larger, with a market value of $11.1B against $4.6B — 2.4× the size. 10x Genomics has negative trailing earnings, so its P/E is not meaningful; Doximity, Inc. trades at 29.6×. Doximity, Inc. grew revenue faster over the last twelve months: 11.2% against −4.28%. Doximity, Inc. has the higher net margin (25.5% vs −12.2%) and the higher return on invested capital (53.1% vs −20.2%). Across the 19 metrics below, Doximity, Inc. leads on 18 and 10x Genomics on 1.
Valuation
Profitability
| Metric | DOCS | TXG | Health Information Services median |
|---|---|---|---|
| Gross margin | 88.07% | 70.03% | 63.38% |
| Operating margin | 29.60% | (14.33%) | (8.35%) |
| Net margin | 25.48% | (12.18%) | (14.70%) |
| Free cash flow margin | 45.31% | 19.68% | 0.58% |
| Return on equity | 17.21% | (9.40%) | (6.82%) |
| Return on assets | 14.60% | (7.47%) | (6.02%) |
| Return on invested capital | 53.13% | (20.20%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack